Edwards Life (EW) Q3 2026 Earnings Call Transcript

Edwards Lifesciences reported Q3 sales of $1.72 billion, up 11.2% in constant currency, and adjusted EPS of $0.80, up 19%; TMTT sales grew 45.6% to $207 million. Management raised full-year sales-growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97–$3.05, citing strong performance and increased TAVR and TMTT outlooks. GAAP EPS was $0.53, primarily reflecting a $220.2 million impairment charge on an R&D asset; the company also reported $700 million in share repurchases year to date.

Analysis

The key change is growth quality, not simply the raised outlook: management expects TAVR expansion to rely more on procedure growth and less on share gains. That supports a larger category but makes EW’s results increasingly dependent on physician referral, center capacity, reimbursement implementation and patient identification—not just product differentiation. The NCD and earlier-treatment evidence are multi-year demand catalysts, but they are unlikely to produce an immediate step-change; operational adoption is the gating item. Management’s emphasis on gradual benefit argues against extrapolating a near-term surge into 2027 estimates before the December outlook and evidence of center-level implementation.

TMTT is the higher-upside, higher-execution-risk leg. New indications and a broader repair/replacement portfolio can build the category, while physician training, procedure capacity, and reimbursement determine conversion. The $2B 2030 ambition should be treated as an option, not a base-case valuation anchor, until adoption and economics are more observable. Competitively, Boston Scientific’s previously disclosed European/OUS exit is now annualized; it is not a fresh tailwind. Other structural-heart competitors can still constrain share and pricing as the market expands.

Near term, the Q4 margin profile is a check on earnings quality: Q3 benefited from FX and planned investment phasing, while management expects lower Q4 operating margins. FX may also reverse. Over 1–3 months, the December investor conference is the next concrete catalyst for 2027 assumptions; over 6–18 months, coverage implementation and evidence-led referral trends matter more than quarterly share movement. The contrarian risk is that investors capitalize a TAM narrative before clinical evidence translates into routine workflows. Thesis weakens if procedure growth stalls, TAVR share declines materially, TMTT growth decelerates, or 2027 margin/growth guidance fails to support the longer-term targets.

Key Decisions for Investors

• Do not chase an earnings-day gap without valuation and post-call price context. Prefer staged EW entries on weakness, contingent on December guidance maintaining credible mid- to high-single-digit TAVR growth and showing a measured path for TMTT; otherwise remain neutral.
• For an existing EW position, separate category growth from share capture: monitor procedure-volume growth, sequential share, and center implementation of the revised coverage policy. Reassess if procedure growth weakens or share losses begin to offset market expansion.
• Treat TMTT’s 2030 target as upside optionality rather than underwriting it as established revenue. Track quarterly year-over-year growth, launch uptake, and evidence of repeatable adoption; slowing growth or weaker-than-expected guidance would challenge the premium-growth thesis.
• Watch Q4 operating margin, constant-currency sales, and the December 2027 outlook. A material miss versus the guided Q4 range or reduced longer-term growth/margin ambitions would falsify the near-term confidence case; absent that, no forced BSX pair trade is warranted because the cited competitive exit is already annualized.